SCHEMBL9104001

SCHEMBL9104001

CO[C@H](C)[C@@H](CN1CCCC1)N(C)C(=O)c1cccc(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ SLC6A2 P23975 2/20 0.44
▸ SLC6A3 Q01959 2/20 0.44
▸ CHRNA1 P02708 1/20 0.44
▸ CHRNG P07510 1/20 0.44
▸ CHRNB1 P11230 1/20 0.44
▸ CHRNB2 P17787 1/20 0.44
▸ CHRNB4 P30926 1/20 0.44
▸ CHRNA3 P32297 1/20 0.44
▸ CHRNA4 P43681 1/20 0.44
▸ CHRND Q07001 1/20 0.44
▸ TDP1 Q9NUW8 2/20 0.43
▸ HPGD P15428 2/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9103007 0.89 CHRNA1 (0.48) RAB9AMAPTL3MBTL1SLC6A2SLC6A3
SCHEMBL9103021 0.89 CHRNA1 (0.48) RAB9AMAPTL3MBTL1SLC6A2SLC6A3
SCHEMBL9099470 0.87 CHRNA1 (0.50) RAB9AMAPTSLC6A2SLC6A3CHRNA1
SCHEMBL9102341 0.86 MAPT (0.46) RAB9AMAPTL3MBTL1SLC6A2SLC6A3
SCHEMBL9102325 0.86 MAPT (0.46) RAB9AMAPTL3MBTL1SLC6A2SLC6A3
SCHEMBL9105377 0.83 MEN1 (0.39) L3MBTL1MEN1ALDH1A1LMNAKMT2A
SCHEMBL9102162 0.81 USP2 (0.52) —
SCHEMBL9104705 0.81 POLB (0.44) L3MBTL1ALDH1A1LMNACHRM2ADRA2B
SCHEMBL9103126 0.80 USP2 (0.42) SLC6A3HPGDSLC6A4
SCHEMBL9103848 0.80 MAPT (0.43) RAB9AMAPTL3MBTL1TDP1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025082731-A1 INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA MOSANNA THERAPEUTICS AG (CH) 2025-04-24 — — WO disclosed
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2013-06-06 — — US disclosed
US-8361998-B2 Compounds and their use as IKACh blockers ASTRAZENECA AB 2013-01-29 — — US disclosed
WO-2012074469-A1 NEW IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 — — WO disclosed
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 RAB9A 1554/4885MAPT 4249/4885L3MBTL1 1425/4885
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 RAB9A 1554/4885MAPT 4249/4885L3MBTL1 1425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback